Results 211 to 220 of about 2,242,189 (260)

Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93. [PDF]

Life (Basel)
Tsoi H, Shi L, Leung MH, Man EPS, So ZQ, Chan WL, Khoo US.   +6 more
europepmc   +1 more source

[Corrigendum] Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. [PDF]

Int J Oncol
Li Z, Yu D, Li H, Lv Y, Li S.
europepmc   +1 more source

Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo

Anti-Cancer Drugs, 2004
We investigated whether it is possible to reduce anti-estrogen resistance using liposomally encapsulated tamoxifen in vivo. Small liposomal vesicles containing up to 5.1 mg tamoxifen/ml liposomal suspension, together with an alkylphospholipid to enhance the cellular uptake, were prepared and characterized.
Zeisig, Reiner, Rückerl, Dominik; id_orcid 0000-0002-0206-1451, Fichtner, Iduna   +2 more
core   +12 more sources

Tamoxifen Resistance in Breast Cancer

Drugs, 2001
Tamoxifen has been used for the systemic treatment of patients with breast cancer for nearly three decades. Treatment success is primarily dependent on the presence of the estrogen receptor (ER) in the breast carcinoma. While about half of patients with advanced ER-positive disease immediately fail to respond to tamoxifen, in the responding patients ...
Dorssers, L.C.J., Flier, S. van der, Brinkmann, A.O., Agthoven, T. van, Veldscholte, J., Berns, E.M.J.J., Klijn, J.G.M., Beex, L.V.A.M., Foekens, J.A.   +8 more
openaire   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

A Review on The Role of VEGF in Tamoxifen Resistance

Anti-Cancer Agents in Medicinal Chemistry, 2019
Background: Certain molecular deviations can lead to the development of breast cancer. For instance, estrogen and estrogen receptors play a significant role in inducing tumor proliferation. However, the efficacy of endocrine therapy through the administration of anti-estrogen drugs, such as Tamoxifen, is challenged by acquired resistance. Methods:
Keivan Majidzadeh-A, Sepideh Mansouri, Leila Farahmand   +2 more
exaly   +3 more sources

Understanding Tamoxifen Resistance in Breast cancer

, 2016
Tamoxifen is the accepted therapy for patients with estrogen receptor α (ERα)−positive breast cancer. However, clinical resistance to tamoxifen, as demonstrated by recurrence or progression on therapy, is frequent and precedes death from metastases. To improve breast cancer treatment it is vital to understand the mechanisms that result in tamoxifen ...
Bekele, Raie Taye
openaire   +2 more sources

Mechanisms of tamoxifen resistance

Breast Cancer Research and Treatment, 1994
Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance.
C K, Osborne, S A, Fuqua
openaire   +2 more sources

Tamoxifen resistance in breast cancer

Critical Reviews in Oncology/Hematology, 1993
Tamoxifen (TAM) resistance is the underlying cause of treatment failure in many breast cancer patients receiving TAM. The mechanism(s) involved in TAM resistance are poorly understood. A variety of mechanisms have been proposed but only limited evidence exists to substantiate them.
V J, Wiebe, C K, Osborne, S A, Fuqua, M W, DeGregorio   +3 more
openaire   +2 more sources

Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance

Cancer Chemotherapy and Pharmacology, 1994
To study tamoxifen resistance-stimulated growth, 30 female ovariectomized nude mice were implanted with tamoxifen-resistant tumors and treated with 10-1000 micrograms/day of tamoxifen citrate subcutaneously. Tamoxifen stimulated MCF-7 tumor growth in a dose-dependent manner, with tumoral tamoxifen concentrations increasing proportionally to the dose (1-
J, Maenpaa, V, Wiebe, G, Wurz, S, Koester, V, Emshoff, R, Seymour, M, DeGregorio   +6 more
openaire   +2 more sources

Tamoxifen resistance: From bench to bedside

European Journal of Pharmacology, 2013
Although tamoxifen is a classical example of a targeted drug, a substantial proportion of estrogen receptor alpha positive breast cancer patients does not benefit from the drug. Over the last few decades, many potential biomarkers have been discovered in cell biological studies that may aid in the prediction of tamoxifen sensitivity and guide in ...
Marjolein, Droog, Karin, Beelen, Sabine, Linn, Wilbert, Zwart   +3 more
openaire   +2 more sources